Checkpoint recovery allows cancer cells to bypass the DNA damage Biology Diagrams

Checkpoint recovery allows cancer cells to bypass the DNA damage Biology Diagrams Introduction. Immune system activation is an extremely effective anticancer therapy that has revolutionised oncological clinical practice over the last decade.1 The immune checkpoint inhibitors (ICIs) are a group of drugs that 'take the brakes' off the normal immune response and facilitate immunological, as opposed to traditional cytotoxic, anti-cancer effects. Retrospective pattern-of-failure data in patients with non-small cell lung cancer (NSCLC) led to the initiation of two prospective randomized trials of local therapy plus systemic therapy versus local therapy alone [16, 17]. Both trials demonstrated that improved PFS could be achieved by treating established tumors present at baseline, but in

Introduction: Despite remarkably improved outcomes with immune checkpoint inhibition, many patients with metastatic melanoma will eventually require further therapy. Chemotherapy has limited activity when used first-line but can alter the tumour microenvironment and does improve efficacy when used in combination with immunotherapy in lung cancer.

Management of multiorgan failure caused by immune checkpoint inhibitor ... Biology Diagrams

Immune checkpoint inhibitors (ICIs) block inhibitory pathways that tumour cells exploit to evade the immune system. They play a key role in the management of aggressive cancers, including non-small cell lung cancer, melanoma and Hodgkin's lymphoma. Despite their efficacy, ICIs can cause severe, potentially fatal, immune-related adverse events (irAEs), including multiorgan failure.

It has been approved as first- or second-line therapy in many cancer types. Unfortunately, a majority of immune checkpoint inhibitor recipients are refractory to the therapy. The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer Pharmacol Ther. 2021 Jan:217:107662. doi: 10.1016/j.pharmthera.2020.107662 Source Reference: Slovin SF "Immune checkpoint combos in metastatic castration-resistant prostate cancer: Where are we going, what are we doing, and why?" J Clin Oncol 2025; DOI: 10.1200/JCO-24-02402.

Neurological complications of immune checkpoint inhibitors: a practical ... Biology Diagrams

This review will focus on three major areas of cell cycle transition control, with particular attention to the alterations found in human cancer. These areas include the G1/S transition, where most cancer‐related defects occur, the G2/M checkpoint and its activation in response to DNA damage, and the spindle checkpoint.